iRhythm Q4 revenue rises 27.1%, beats analyst estimates

iRhythm Holdings

19/02/2026 21:34

Overview

Digital health care firm's Q4 revenue rose 27.1%, beating analyst expectations

Adjusted EPS for Q4 beat analyst expectations

Company achieved first positive GAAP net income in its history

Outlook

iRhythm expects 2026 revenue between $870 mln and $880 mln

Company anticipates 2026 adjusted EBITDA margin of 11.5% to 12.5%

Result Drivers

INCREASED DEMAND - Revenue growth driven by increased demand for Zio services and favorable pricing

OPERATIONAL EFFICIENCIES - Gross margin improvement attributed to scale and manufacturing efficiencies

INVESTMENTS FOR GROWTH - Increased operating expenses due to volume-related costs and growth investments

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$208.90 mln
$201.59 mln (15 Analysts)
Q4 Adjusted EPS
Beat
$0.29
$0.03 (11 Analysts)
Q4 Net Income
$5.60 mln
Q4 Gross Margin
70.90%
Q4 Gross Profit
$148.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for iRhythm Holdings, Inc is $220.00, about 43% above its February 18 closing price of $153.85

Press Release: ID:nGNX71TtjP

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)